These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 12733498)

  • 1. [How antiretroviral medicines work].
    Iofolla M
    Sidahora; 2003; (1):18-21. PubMed ID: 12733498
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiretroviral update: recent advances expand options for patients with HIV.
    Santhanam H; Goins M
    Adv Nurse Pract; 2004 Nov; 12(11):53-4, 56. PubMed ID: 15559568
    [No Abstract]   [Full Text] [Related]  

  • 3. What's in the works.
    Horn T
    Posit Living; 2001 Feb; 10(2):20-2. PubMed ID: 11548496
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
    Miller JF; Brieger M; Furfine ES; Hazen RJ; Kaldor I; Reynolds D; Sherrill RG; Spaltenstein A
    Bioorg Med Chem Lett; 2005 Aug; 15(15):3496-500. PubMed ID: 15990305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biological basis for generating resistance to antiretroviral drugs].
    Alcamí J; Delgado R; Menéndez-Arias L
    Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):3-13. PubMed ID: 11428056
    [No Abstract]   [Full Text] [Related]  

  • 6. [German-Austrian guidelines for antiretroviral therapy of HIV infection. (July, 2002, update)].
    Brockmeyer NH; ;
    Dtsch Med Wochenschr; 2003 May; 128 Suppl 1():S7-18. PubMed ID: 12736863
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting HIV attachment and entry for therapy.
    Strizki J
    Adv Pharmacol; 2008; 56():93-120. PubMed ID: 18086410
    [No Abstract]   [Full Text] [Related]  

  • 8. [Mechanisms of HIV replication and anti-HIV drug action].
    Koyanagi Y; Watanabe T
    Nihon Rinsho; 2010 Mar; 68(3):378-81. PubMed ID: 20229777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transmitted multidrug resistant HIV-1: new and investigational therapeutic approaches.
    Shet A; Markowitz M
    Curr Opin Investig Drugs; 2006 Aug; 7(8):709-20. PubMed ID: 16955682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drugs for old.
    Winston A; Stebbing J
    J HIV Ther; 2005 Mar; 10(1):11-6. PubMed ID: 15951729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decrease of replicative capacity of HIV isolates after genotypic guided change of therapy.
    Sarmati L; Nicastri E; Montano M; Dori L; Buonomini AR; d'Ettorre G; Gatti F; Parisi SG; Vullo V; Andreoni M
    J Med Virol; 2004 Apr; 72(4):511-6. PubMed ID: 14981751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tannin inhibits HIV-1 entry by targeting gp41.
    Lü L; Liu SW; Jiang SB; Wu SG
    Acta Pharmacol Sin; 2004 Feb; 25(2):213-8. PubMed ID: 14769212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes.
    Clayton R; Ohagen A; Nicol F; Del Vecchio AM; Jonckers TH; Goethals O; Van Loock M; Michiels L; Grigsby J; Xu Z; Zhang YP; Gutshall LL; Cunningham M; Jiang H; Bola S; Sarisky RT; Hertogs K
    Antiviral Res; 2009 Nov; 84(2):142-9. PubMed ID: 19699239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-HIV properties of cationic fullerene derivatives.
    Marchesan S; Da Ros T; Spalluto G; Balzarini J; Prato M
    Bioorg Med Chem Lett; 2005 Aug; 15(15):3615-8. PubMed ID: 15978810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why HIV drug resistance matters: an overview.
    Learned J
    Posit Aware; 2005; 16(5):26-30. PubMed ID: 16220604
    [No Abstract]   [Full Text] [Related]  

  • 16. Update of the drug resistance mutations in HIV-1: 2004.
    Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
    Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
    [No Abstract]   [Full Text] [Related]  

  • 17. Dynamics of HIV replication in lymphocytes and the efficacy of protease inhibitors.
    Bermejo M; Sánchez-Palomino S; Usán L; Alcamí J
    J Med Virol; 2004 Aug; 73(4):502-7. PubMed ID: 15221892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends. Aging HIV population faces unique health challenges, officials say.
    AIDS Policy Law; 2010 Oct; 25(11):1, 4. PubMed ID: 21053399
    [No Abstract]   [Full Text] [Related]  

  • 19. Heterobiaryl human immunodeficiency virus entry inhibitors.
    Lu RJ; Tucker JA; Pickens J; Ma YA; Zinevitch T; Kirichenko O; Konoplev V; Kuznetsova S; Sviridov S; Brahmachary E; Khasanov A; Mikel C; Yang Y; Liu C; Wang J; Freel S; Fisher S; Sullivan A; Zhou J; Stanfield-Oakley S; Baker B; Sailstad J; Greenberg M; Bolognesi D; Bray B; Koszalka B; Jeffs P; Jeffries C; Chucholowski A; Sexton C
    J Med Chem; 2009 Jul; 52(14):4481-7. PubMed ID: 19534463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
    Miller JF; Furfine ES; Hanlon MH; Hazen RJ; Ray JA; Robinson L; Samano V; Spaltenstein A
    Bioorg Med Chem Lett; 2004 Feb; 14(4):959-63. PubMed ID: 15013001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.